A Case of Prekallikrein Deficiency in a Pediatric Patient.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4100-4100 ◽  
Author(s):  
Shannon L. Carpenter ◽  
Howard A. Britton

Abstract Prekallikrein (also known as Fletcher factor) is described as one of the contact factors, and when converted to its active form, kallikrein, is responsible for the activation of factor XII and initiation of the intrinsic pathway of the coagulation cascade. Kallikrein also converts high-molecular-weight kininogen to bradykinin, which acts as a potent vasodilator. Deficiency of prekallikrein was first described in 1965 as an autosomal recessive disorder. Hereditary deficiency of prekallikrein is not associated with a clinical bleeding disorder, but does result in a prolonged activated partial thromboplastin time (aPTT). Most cases of prekallikrein deficiency are identified through routine screening. We present a young man who was referred to our Hemophilia and Thrombophilia Treatment Center for a significantly prolonged aPTT and subsequently found to have prekallikrein deficiency. NP is a 7 year-old boy who was found to have an aPTT of 209.6 seconds on pre-operative evaluation for PE tubes and adenoidectomy. Prothrombin time (PT) was normal at 14.7 seconds, with an INR of 1.2. There was no personal or family history of bleeding. Past medical history did include bipolar disorder and attention deficit disorder, for which the patient was taking olanzapine and depakote. A 1:1 mixing study with normal plasma led to complete correction of the aPTT to 28.9 sesconds. Levels of factors VIII, IX, XI, and XII were normal at 98%, 92%, 99% and 129%, respectively. High molecular weight kininogen level was also normal. Thrombin time was normal at 17.1 sec. An incubated aPTT was performed over 3 hours with decrease in the aPTT from 179 seconds to 72 seconds, a phenomenon that has been reported previously, and is thought to be due to auto-activation of factor XII. Prekallikrein was measured at less that 15% (normal reference 55–207%). The patient subsequently underwent adeno-tonsillectomy without any excessive bleeding. This case serves as another example of the benign causes for a prolonged aPTT in the pre-operative setting in addition to those such as lupus anticoagulant or factor XII deficiency. Deficiency of prekallikrein should be included in the differential diagnosis of a prolonged aPTT, particularly in the absence of bleeding symptoms.

1984 ◽  
Vol 52 (03) ◽  
pp. 221-223 ◽  
Author(s):  
M Christe ◽  
P Gattlen ◽  
J Fritschi ◽  
B Lämmle ◽  
W Berger ◽  
...  

SummaryThe contact phase has been studied in diabetics and patients with macroangiopathy. Factor XII and high molecular weight kininogen (HMWK) are normal. C1-inhibitor and also α2-macroglobulin are significantly elevated in diabetics with complications, for α1-macroglobulin especially in patients with nephropathy, 137.5% ± 36.0 (p <0.001). C1-inhibitor is also increased in vasculopathy without diabetes 113.2 ± 22.1 (p <0.01).Prekallikrein (PK) is increased in all patients’ groups (Table 2) as compared to normals. PK is particularly high (134% ± 32) in 5 diabetics without macroangiopathy but with sensomotor neuropathy. This difference is remarkable because of the older age of diabetics and the negative correlation of PK with age in normals.


2004 ◽  
Vol 91 (01) ◽  
pp. 61-70 ◽  
Author(s):  
Baby Tholanikunnel ◽  
Berhane Ghebrehiwet ◽  
Allen Kaplan ◽  
Kusumam Joseph

SummaryCell surface proteins reported to participate in the binding and activation of the plasma kinin-forming cascade includes gC1qR, cytokeratin 1 and u-PAR. Each of these proteins binds high molecular weight kininogen (HK) as well as Factor XII. The studies on the interaction of these proteins, using dot-blot analysis, revealed that cytokeratin 1 binds to both gC1qR and u-PAR while gC1qR and u-PAR do not bind to each other. The binding properties of these proteins were further analyzed by gel filtration. When biotinylated cytokeratin 1 was incubated with either gC1qR or u-PAR and gel filtered, a new, higher molecular weight peak containing biotin was observed indicating complex formation. The protein shift was also similar to the biotin shift. Further, immunoprecipitation of solubilized endothelial cell plasma membrane proteins with anti-gC1qR recovered both gC1qR and cytokeratin 1, but not u-PAR. Immunoprecipitation with anti-u-PAR recovered only u-PAR and cytokeratin 1. By competitive ELISA, gC1qR inhibits u-PAR from binding to cytokeratin 1; u-PAR inhibits gC1qR binding to a lesser extent and requires a 10-fold molar excess. Our data suggest that formation of HK (and Factor XII) binding sites along endothelial cell membranes consists of bimolecular complexes of gC1qR-cytokeratin 1 and u-PAR-cytokeratin 1, with gC1qR binding being favored.


Blood ◽  
1980 ◽  
Vol 55 (1) ◽  
pp. 156-159 ◽  
Author(s):  
L Vroman ◽  
AL Adams ◽  
GC Fischer ◽  
PC Munoz

Abstract Using ellipsometry, anodized tantalum interference color, and Coomassie blue staining in conjunction with immunologic identification of proteins adsorbed at interfaces, we have previously found that fibrinogen is the main constituent deposited by plasma onto many man- made surfaces. However, the fibrinogen deposited from normal plasma onto glass and similar wettable materials is rapidly modified during contact activation until it can no longer be identified antigenically. In earlier publications, we have called this modification of the fibrinogen layer “conversion,” to indicate a process of unknown nature. Conversion of adsorbed fibrinogen by the plasma was not accompanied by marked change in film thickness, so that we presumed that this fibrinogen was not covered but replaced by other protein. Conversion is now showen to be markedly delayed in plasma lacking high molecular weight kininogen, slightly delayed in plasma lacking factor XII, and normal in plasma that lack factor XI or prekallikrein. We conclude that intact plasma will quickly replace the fibrinogen it has deposited on glass-like surfaces by high molecular weight kininogen and, to a smaller extent, by factor XII. Platelets adhere preferentially to fibrinogen-coated surfaces; human platelets adhere to hydrophobic nonactivating surfaces, since on these, adsorbed firbinogen is not exchanged by the plasma. The adsorbed fibrinogen will be replaced on glass-like surfaces during surface activation of clotting, and platelets failing to find fibrinogen will not adhere.


2000 ◽  
Vol 23 (3) ◽  
pp. 199-206 ◽  
Author(s):  
U. Julius ◽  
G. Siegert ◽  
S. Gromeier

We performed an intraindividual comparison of the effect on the coagulation system of two selective apheresis procedures: Direct Adsorption of Lipoproteins (DALI) and Heparin-induced Lipoprotein Fibrinogen Precipitation (HELP). Six patients suffering from heterozygous familial hypercholesterolemia have been treated with 2 sessions of each procedure. Anticoagulation was carried out according to usual recommendations. Blood samples were taken before, immediately after and on the second day after the sessions. We assessed global coagulation tests (prothrombin time, activated partial thromboplastin time), fibrinogen, prothrombin fragment F 1 + 2 and a variety of factors (Factors II, V, VII, XIII, IX, X, XI, XII, XIIa; von Willebrand Factor; collagen-binding activity, prekallikrein, high-molecular weight kininogen) and antagonists (antithrombin III, protein S activity, free protein S). In fact, all parameters measured have been influenced by the apheresis treatment. Fibrinogen is lowered more by HELP, which also has a more definite impact on factors belonging to the prothrombin complex (II, VII, X). In contrast, the major effects of the DALI system have been seen on the intrinsic pathway of the coagulation system (IX, XI, prekallikrein, high-molecular-weight kininogen). With both systems, no increases in activated Factor XII or in prothrombin fragment F1 + 2 have been observed. These data provide a solid basis for individual adaptations of anticoagulant doses.


Sign in / Sign up

Export Citation Format

Share Document